Next Article in Journal
Prediction of Protein–Ligand Interaction Based on the Positional Similarity Scores Derived from Amino Acid Sequences
Next Article in Special Issue
Dissecting Molecular Features of Gliomas: Genetic Loci and Validated Biomarkers
Previous Article in Journal
Correction: Sciacca, F. L., et al. Microduplication of 15q13.3 and Microdeletion of 18q21.32 in a Patient with Moyamoya Syndrome. Int. J. Mol. Sci. 2018, 19, 3675
Previous Article in Special Issue
Prion Protein in Glioblastoma Multiforme
Open AccessReview

How to Make Anticancer Drugs Cross the Blood–Brain Barrier to Treat Brain Metastases

by 1,2,*, 1,3, 1,4,5,6 and 1,2,7,*
1
Institut National de la Santé Et de la Recherche Médicale (INSERM), U942, 9 Rue de Chablis, 93000 Bobigny, France
2
Assistance Publique Hôpitaux de Paris, Avicenne Hospital, Department of medical oncology, 93000 Bobigny, France
3
Medical Oncology Department A, National Cancer Hospital, Ha Noi 110000, Viet Nam
4
AP-HP Saint-Louis Hospital, Laboratory of Pathology, 75010 Paris, France
5
Paris Diderot University/ Université Sorbonne Paris Cité, 5 rue Thomas Mann, 75013 Paris, France
6
INSERM, U1165, 1 Avenue Claude Vellefaux, 75010 Paris, France
7
Paris 13 University, 99 Avenue Jean Baptiste Clément, 93430 Villetaneuse, France
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(1), 22; https://doi.org/10.3390/ijms21010022
Received: 23 November 2019 / Revised: 10 December 2019 / Accepted: 16 December 2019 / Published: 18 December 2019
(This article belongs to the Special Issue Molecular Biology of Brain Tumors)
The incidence of brain metastases has increased in the last 10 years. However, the survival of patients with brain metastases remains poor and challenging in daily practice in medical oncology. One of the mechanisms suggested for the persistence of a high incidence of brain metastases is the failure to cross the blood–brain barrier of most chemotherapeutic agents, including the more recent targeted therapies. Therefore, new pharmacological approaches are needed to optimize the efficacy of anticancer drug protocols. In this article, we present recent findings in molecular data on brain metastases. We then discuss published data from pharmacological studies on the crossing of the blood–brain barrier by anticancer agents. We go on to discuss future developments to facilitate drug penetration across the blood–brain barrier for the treatment of brain metastases among cancer patients, using physical methods or physiological transporters. View Full-Text
Keywords: brain metastases; blood–brain barrier; blood–tumor barrier; copy number profiling; mutation; anticancer drugs; pharmacokinetics brain metastases; blood–brain barrier; blood–tumor barrier; copy number profiling; mutation; anticancer drugs; pharmacokinetics
Show Figures

Figure 1

MDPI and ACS Style

Angeli, E.; Nguyen, T.T.; Janin, A.; Bousquet, G. How to Make Anticancer Drugs Cross the Blood–Brain Barrier to Treat Brain Metastases. Int. J. Mol. Sci. 2020, 21, 22. https://doi.org/10.3390/ijms21010022

AMA Style

Angeli E, Nguyen TT, Janin A, Bousquet G. How to Make Anticancer Drugs Cross the Blood–Brain Barrier to Treat Brain Metastases. International Journal of Molecular Sciences. 2020; 21(1):22. https://doi.org/10.3390/ijms21010022

Chicago/Turabian Style

Angeli, Eurydice; Nguyen, Thuy T.; Janin, Anne; Bousquet, Guilhem. 2020. "How to Make Anticancer Drugs Cross the Blood–Brain Barrier to Treat Brain Metastases" Int. J. Mol. Sci. 21, no. 1: 22. https://doi.org/10.3390/ijms21010022

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop